CB2 Insights Signs Agreement with Premier Health to Integrate Medical Cannabis Clinical Decision Support Tool

CB2 Insights (CSE:CBII)(“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, has initiated integration with Premier Health Group (CSE:PHGI), a leading Electronic Medical Records (EMR) platform.

The agreement will give the more than 4,600 physicians and healthcare practitioners using Premier Health’s Juno EMR platform access to the industry’s only medical cannabis-specific Clinical Decision Support (“CDS”) tool. CB2 Insights’ CDS tool is designed to help healthcare providers considering integrating medical cannabis into a patient’s treatment plans. This first-of-its-kind integration in the sector will allow physicians and healthcare practitioners to overcome many of the barriers they face from a lack of access to medical cannabis education, qualification factors, risk factors and benefits on a patient-by-patient basis using clinically-led, evidence-based data.

“For the past 4 years, we have worked toward simplifying the process for a physician to determine the appropriateness and potential efficacy of medical cannabis as an option within a patient’s treatment plan,” said Prad Sekar, CEO of CB2 Insights. “We are now in a position to benefit from the aggregated and anonymized data gathered from more than 300,000 patient visits in a clinical environment along with the hundreds of clinical trials and observational studies that are collectively used to power our CDS tool. Clinicians can use this point-of-care application to help them incorporate cannabis as a treatment option into their practice and create improved access for patients who can benefit from cannabinoid therapy.”

CB2 Insights, through its clinical arm in the U.S., operates 28 medical cannabis evaluation centers staffed with physicians and healthcare practitioners and creates access for patients who qualify for medical cannabis as well as a center of excellence to study and understand the clinical outcomes of cannabinoid therapy. CB2 gathers data at the point-of-care in a HIPAA-compliant manner, both aggregated and anonymized, to study trends and outcomes that work to educate and support stakeholders including but not limited to physicians and other healthcare professionals.

“We are dedicated to finding new ways to create value for our physician network,” said Dr. Essam Hamza, CEO of Premier Health. “We continue to receive multiple requests from physicians who ask about how best to incorporate medical cannabis into their clinics. This agreement with CB2 will provide us a robust, validated tool to give our physicians and healthcare practitioners a safe and secure way to qualify, educate and where appropriate, prescribe medical cannabis to their patients in a compliant manner.”

As part of the agreement, CB2 will provide the development and continuous maintenance and support of the CDS tool and all related technologies. Premier Health will support the partnership by providing access to their software and will engage its network of physicians and other healthcare professionals to assist in the adoption of the CDS tool.

About CB2 Insights

CB2 Insights has a mission to mainstream medical cannabis into traditional healthcare. We do so by gathering data and creating objective real-world evidence through our proprietary software and service brands. Using clinical management and data collection software at the point-of-care, CB2 Insights and its group of sub-brands has become a leading force behind bringing traditional healthcare protocols to the rapidly evolving global cannabis industry.

For more information please visit www.cb2insights.com.

About Premier Health

Premier Health is a Canadian company that is strategically poised to take advantage of business opportunities in the global health care industry. We are focused on innovative health care approaches that combine human skill-based expertise with emerging technologies. Premier Health, in conjunction with its subsidiary Cloud Practice, a cloud-based SAAS Electronic Medical Records software company, is developing proprietary technology to deliver quality healthcare through the combination of connected primary care clinics with telemedicine and artificial intelligence (AI). We currently have a combined ecosystem of 290 clinics, over 3000 licensed practitioners and almost 3 million registered patients. The Premier Health team has deep clinical, operational and financial expertise and a passion for improving healthcare for all patients.

For more information on Juno EMR, please visit www.junoemr.com.

Forward Looking Statements

Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in CB2’s filings with Canadian securities regulators. When used in this news release, words such as “will, could, plan, estimate, expect, intend, may, potential, believe, should,” and similar expressions, are forward-looking statements.

Forward-looking statements may include, without limitation, statements regarding the opportunity to provide services and software to the U.S. cannabis industry.

Although CB2 has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: dependence on obtaining regulatory approvals; investing in target companies or projects which have limited or no operating history and are subject to inconsistent legislation and regulation; change in laws; reliance on management; requirements for additional financing; competition; hindering market growth and state adoption due to inconsistent public opinion and perception of the medical-use and recreational-use marijuana industry and; regulatory or political change.

There can be no assurance that such information will prove to be accurate or that management’s expectations or estimates of future developments, circumstances or results will materialize. As a result of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.

Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. CB2 disclaims any intention or obligation to update or revise such information, except as required by applicable law, and CB2 does not assume any liability for disclosure relating to any other company mentioned herein.

No securities regulator or exchange has reviewed, approved, disapproved, or accepts responsibility for the content of this news release.

Primary Contact:

Dan Thompson

Chief Marketing Officer – CB2 Insights

1.416.670.9316

For Investor Inquiries:

Sophic Capital

1.647.362.8286

For Media Inquiries:

KCSA Strategic Communications

Click here to connect with CB2 Insights (CSE:CBII) for an Investor Presentation. 

Source: www.globenewswire.com